TGTX
HealthcareTG Therapeutics, Inc. · Biotechnology · $6B
What is TG Therapeutics, Inc.?
TG Therapeutics is a commercial-stage biopharmaceutical company targeting B-cell malignancies and autoimmune diseases. Headquartered in Morrisville, NC, the company has advanced multiple therapeutic candidates from clinical development into commercialization.
The company develops and commercializes treatments for conditions including relapsing multiple sclerosis, chronic lymphocytic leukemia, and certain lymphomas. Revenue is generated through product sales and collaboration agreements with pharmaceutical partners. Its pipeline spans monoclonal antibodies, oral kinase inhibitors, and bispecific antibody platforms, giving it multiple shots at durable commercial success across oncology and autoimmune indications.
TG Therapeutics was founded in 2010 and is headquartered in Morrisville, North Carolina.
- Ublituximab — glycoengineered monoclonal antibody for multiple sclerosis and B-cell cancers
- Umbralisib — oral PI3K-delta and CK1-epsilon inhibitor for lymphoma and CLL
- TG-1701 — selective oral BTK inhibitor in clinical development
- TG-1801 — bispecific CD47/CD19 antibody candidate
- Cosibelimab — PD-L1 monoclonal antibody developed via Checkpoint Therapeutics collaboration
Is TGTX a Good Stock to Buy?
UQS Score rates TGTX as Good overall, reflecting a company in active commercial transition with meaningful upside potential alongside notable risks.
The Growth pillar stands out as the clearest strength — TGTX is expanding its commercial footprint from a recently launched product base, and the Risk pillar rating of Good suggests the balance sheet and operational profile are not flashing immediate alarm signals. Quality is rated Good as well, pointing to a business that is maturing beyond pure cash-burn territory.
The Moat pillar registers as Neutral, indicating the company has not yet built the durable competitive advantages seen in larger biopharma peers. Valuation is rated Elevated, meaning the market may already be pricing in a favorable commercial trajectory.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TGTX pay dividends?
No — TG Therapeutics, Inc. does not currently pay a dividend.
TGTX does not currently pay a dividend, which is typical for commercial-stage biopharmaceutical companies. Capital is directed toward clinical development, commercial infrastructure, and pipeline expansion rather than shareholder distributions. Investors in this name are generally seeking growth from product launches and pipeline milestones rather than income.
When does TGTX report earnings?
TG Therapeutics reports earnings on a quarterly cadence, consistent with US-listed public companies.
Quarterly results have increasingly reflected the commercial ramp of the company's approved product, with revenue trends drawing attention from growth-oriented investors. Pipeline updates and collaboration milestones often accompany financial disclosures and can meaningfully move the stock.
For the most recent quarter's results and guidance, visit TG Therapeutics' investor relations page directly.
TGTX Price History
+4.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in TG Therapeutics, Inc.?
Based on TG Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TGTX Long-term Outlook
The Strong Growth pillar rating suggests TGTX's commercial trajectory is among the more compelling in the mid-cap biopharma space. Product adoption curves for recently launched therapies, combined with a pipeline that spans oncology and autoimmune indications, provide multiple potential revenue contributors over the medium term. However, the Elevated Valuation pillar signals that much of this optimism may already be reflected in the share price, leaving limited margin for execution shortfalls.
Growth drivers
- Continued commercial uptake of approved multiple sclerosis and oncology therapies
- Pipeline advancement across BTK inhibitor and bispecific antibody programs
- Collaboration and licensing agreements that can generate milestone and royalty revenue
Key risks
- Elevated valuation leaves little room for commercial or clinical disappointments
- Neutral Moat rating reflects competitive pressure from larger, better-resourced biopharma peers
- Clinical-stage programs carry binary event risk that can sharply affect sentiment
TGTX vs Peers
TGTX operates in a competitive biopharma landscape alongside companies pursuing distinct therapeutic strategies.
CRISPR Therapeutics pursues gene-editing technology rather than antibody or small-molecule approaches, targeting a different layer of disease biology.
Scholar Rock focuses on protein growth factor modulation, giving it a distinct mechanism of action compared to TGTX's B-cell and autoimmune focus.
Alkermes is a more diversified commercial biopharma with an established CNS and addiction medicine portfolio, offering a different risk and revenue profile.
Frequently Asked Questions
What does TG Therapeutics do?
TG Therapeutics develops and commercializes treatments for B-cell malignancies and autoimmune diseases. Its portfolio includes approved therapies for relapsing multiple sclerosis and clinical-stage candidates targeting lymphoma, CLL, and related conditions. The company also maintains collaboration agreements with several pharmaceutical partners.
Does TGTX pay dividends?
TGTX does not pay a dividend. As a commercial-stage biopharmaceutical company, it reinvests available capital into product commercialization and pipeline development. Investors in TGTX are generally seeking capital appreciation from clinical and commercial milestones rather than income.
When does TGTX report earnings?
TG Therapeutics reports on a quarterly cadence, as is standard for US-listed companies. Exact dates shift each quarter. For the most current schedule, check the investor relations section of the company's official website.
Is TGTX a good stock to buy?
UQS Score rates TGTX as Good overall. The Growth pillar is rated Strong and Quality and Risk are both rated Good, reflecting a company in active commercial expansion. The Valuation pillar is rated Elevated, which warrants attention. The full pillar breakdown is available to Pro members.
Is TGTX overvalued?
The UQS Valuation pillar for TGTX is rated Elevated, suggesting the market is pricing in a favorable growth scenario. Whether that premium is justified depends on commercial execution and pipeline progress. Investors should weigh this against the Strong Growth rating when forming a view.
How does TGTX compare to its competitors?
TGTX focuses on B-cell biology and autoimmune disease through monoclonal antibodies and small-molecule inhibitors. Peers like CRISPR Therapeutics pursue gene-editing platforms, Scholar Rock targets protein modulation, and Alkermes operates a broader CNS-focused commercial business — each representing a meaningfully different therapeutic and business model approach.
What is TGTX's market cap bracket?
TGTX is classified as a mid-cap stock. This places it in a tier where commercial traction is established but the company has not yet reached the scale of large-cap biopharma peers. Mid-cap biotechs often carry higher volatility relative to their larger counterparts.
Who founded TG Therapeutics?
TG Therapeutics was incorporated in 2010. Founding and leadership history is publicly available through the company's official filings and investor relations materials for those seeking detailed background.
Is TGTX a long-term quality investment?
From a quality-indicator perspective, TGTX scores Good on the UQS composite. The Strong Growth and Good Risk ratings are constructive for long-term holders, but the Neutral Moat and Elevated Valuation pillars suggest the long-term thesis depends heavily on sustained commercial execution and pipeline delivery.
What is the main competitive advantage of TG Therapeutics?
TGTX's differentiation lies in its glycoengineered antibody technology and its combination approach targeting multiple mechanisms in B-cell diseases. However, the UQS Moat pillar is rated Neutral, indicating these advantages are not yet considered deeply entrenched relative to the broader competitive landscape.
What sector does TGTX belong to?
TGTX operates in the Healthcare sector, specifically within commercial-stage biopharmaceuticals. It focuses on oncology and autoimmune disease — two of the most active and competitive therapeutic areas in the industry. You can explore other [healthcare stocks scored by UQS](/sector/healthcare) for broader context.
Is TGTX a growth stock or value stock?
Based on UQS pillar ratings, TGTX leans clearly toward the growth category. The Growth pillar is rated Strong while the Valuation pillar is rated Elevated — a combination typical of growth-oriented names where investors are paying a premium for future commercial and clinical potential.
Unlock Full TGTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare TGTX against scored sector peers
- ✓Track pillar changes as new data arrives
- ✓Screen for stocks with similar Growth and Risk profiles
Pro Analysis
TGTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 57.4 | 69.3 | 42.0 | 81.8 | 48.5 | 39.3 | -1.3 |
| May 7, 2026 | 58.7 | 70.1 | 42.0 | 80.2 | 65.8 | 32.1 | -1.2 |
| May 3, 2026 | 59.9 | 70.1 | 42.0 | 80.2 | 65.8 | 39.8 | +0.5 |
| May 2, 2026 | 59.4 | 70.1 | 42.0 | 80.2 | 65.8 | 36.8 | +0.1 |
| Apr 26, 2026 | 59.3 | 70.1 | 42.0 | 80.0 | 65.8 | 36.1 | -0.2 |
| Apr 24, 2026 | 59.5 | 70.1 | 42.0 | 80.0 | 65.8 | 37.4 | -0.1 |
| Apr 19, 2026 | 59.6 | 70.1 | 42.0 | 80.2 | 65.8 | 38.1 | -0.4 |
| Apr 18, 2026 | 60.0 | 70.1 | 42.0 | 80.3 | 65.8 | 40.2 | -4.0 |
| Apr 14, 2026 | 64.0 | 70.1 | 42.0 | 80.3 | 65.8 | 66.9 | -0.1 |
| Apr 12, 2026 | 64.1 | 70.1 | 42.0 | 80.3 | 65.8 | 67.4 | 0.0 |
TGTX — Pillar Breakdown
Quality
— 69.3/100 (25%)TG Therapeutics, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 81.8/100 (20%)TG Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 48.5/100 (15%)TG Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 39.3/100 (15%)TG Therapeutics, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)TG Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TGTX.
Score Composition
Financial Data
More Stock Analysis
How is the TGTX UQS Score Calculated?
The UQS (Unified Quality Score) for TG Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses TG Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether TG Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.